PanamaTimes

Thursday, Dec 26, 2024

Efficacy of Pfizer’s Covid-19 pill questioned

Efficacy of Pfizer’s Covid-19 pill questioned

An Israeli study has indicated the medication is of little measurable benefit to patients in the 40-65 age bracket
A Covid-19 pill lauded by the World Health Organization (WHO) may be of little or no benefit to patients aged between 40 and 65, a new study by Israeli researchers has suggested. The medication, made by Pfizer and sold under the trade name Paxlovid, has proven effective in those aged over 65, however.

Published in the New England Journal of Medicine on Wednesday, the study involved 109,000 patients who had received Paxlovid. After analyzing different age brackets, the scientists concluded that the treatment did little to improve the conditions of patients aged 40 to 65. At the same time, the medication reduced the number of hospitalizations among seniors by approximately 75%, if given shortly after contracting Covid-19.

The analysis, however, is based on data obtained from the Israeli health system as opposed to observing patients in a randomized study with a control group – something which represents a departure from practices held as the standard for such research, AP pointed out.

No official comment from Pfizer has been forthcoming as of yet.

The US Food and Drug Administration authorized Paxlovid late last year for adults and children over 12 who suffer from chronic conditions like obesity, diabetes and heart disease. According to federal records cited by AP, over 3.9 million prescriptions for the medication have been issued since the drug was given the green light.

The Biden administration has been placing particular emphasis on Paxlovid in the hope of reducing the number of hospitalizations. US authorities are said to have shelled out some $10 billion to procure the drug, which is being made available to the public at thousands of pharmacies through the government’s test-and-treat initiative.

In an emailed statement on Wednesday, White House spokesperson Kevin Munoz cited several other studies which indicate that Paxlovid helps reduce hospitalizations among people 50 and older. That research, however, has yet to be published in peer-reviewed journals, AP noted.

The official was quoted as saying that the “growing body of evidence is showing that individuals between the ages of 50 and 64 can also benefit from Paxlovid.”
Comments

Oh ya 2 year ago
I think I read somewhere it was the liver and kidneys that it also is harmful to. But of you have taken the shot and especially the boosters then this pill is the least of your problems

Newsletter

Related Articles

PanamaTimes
0:00
0:00
Close
The Closure of the Global Engagement Center: Controversy, Claims, and Conclusions
The American Democrats Party Strives to Rise from the Ashes
Trump Nominates Kevin Marino Cabrera as Ambassador to Panama Amid Canal Dispute
Texas Congresswoman Kay Granger Located in Nursing Home Following Six Months of Inactivity
A large group of unauthorized migrants is traveling through Mexico with the aim of reaching the USA before Trump assumes office.
A Democrat Congresswoman with blue and black hair is having a breakdown over "President Musk."
Argentina Defies Predictions with Record $17 Billion Trade Surplus, But Is the Growth Sustainable?
Disney's High Seas Gamble: Navigating the Waters of Cruise Expansion
The Surprising Impact of Extreme Heat on Mexico's Youth
Polarization: The Word That Unites a Divided Era
Exoneration in the Subway: The Complexities of Self-Defense and Public Safety
The Tragic Passing of UnitedHealthcare CEO Highlights Corporate Security Challenges
Global Developments: Violence in Sinaloa, Political Chaos in the Bahamas, Venezuelan Voting Disputes, and a Major UK Drug Bust
OpenAI and Anduril: Charting AI's Path in Modern Warfare
The Pardon of Hunter Biden: A Symbol of Hypocrisy
Biden Crafted the Strategy Used by Trump
South Korea's Democracy Tested: President Yoon’s Martial Law Reversal Sparks Political Reckoning
Seoul Crisis: Yoon Suk Yeol's Martial Law Blunder Triggers Political Upheaval
Generative AI's Limited Impact on Elections Highlighted by Meta
France at the Precipice: Barnier’s Administration Confronts Unprecedented No-Confidence Vote
Jaguar Unveils Electric Concept Car, Type 00
White House Defends Presidential Pardon of Hunter Biden
xAI by Elon Musk: Transforming Ambition with a $50 Billion Valuation
President-elect Donald Trump, has announced on Truth Social that Kashyap "Kash" Patel, will be the next Director of the FBI
A Historic Milestone or Risky Precedent? The Assisted Dying Bill Splits both Parliament and the Nation in England and Wales
Trump's Tariff Threat Looms Large as Trudeau Heads to Mar-a-Lago for Talks
Canada's Oil Industry Faces Uncertainty Amidst Trump's Tariff Threat
World Court to Assess Global Legal Responsibilities on Climate Change
What the Pink Elephant Test Reveals About Thought Control
Trudeau Visits Trump in Florida Amid Rising Tariff Concerns
Is Elon Musk the Unofficial President of America?
Impact of Proposed US Tariffs on Canadian Oil Exports
U.S. policymakers face a contentious debate over whether to engage with Nicolás Maduro's regime in Venezuela.
COP29's Carbon Trading Deal Faces Major Criticisms
Indian Diplomats in Canada Monitored: Government Raises Alarm
Putin Warns Trump of Ongoing Safety Concerns
Claudia Sheinbaum Challenges Trump's Migration Claims
Insights from Dostoevsky: The Impact of Self-Deception
Trump Administration Nominees Face Threats, FBI Confirms
Elon Musk Criticizes Fighter Jets, Advocates for Drone Warfare
Kim Kardashian's Social Media Activity Fuels Political Speculation
An Examination of AI's Influence on Future Work and Life
Tulsi Gabbard's Contentious Nomination for Director of National Intelligence
$100,000 Trump Watch Faces Slow Sales
Surge in Golden Visa Interest Among Americans Post-Trump Election
Elon Musk and Vivek Ramaswamy Aim to Reduce US Federal Spending
Donald Trump nominated Linda McMahon for the position of Secretary of Education.
Russia Pledges Response Following Ukraine's Use of US Long-Range Missiles
Joe Biden Joins G20 Leaders' Photo Re-Take in Rio
Trump Plans to Reverse Biden's Fuel and EV Regulations
×